Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.50 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18548333 | 0.97 | DDB1 (0.50) | DDB1CRBNALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL16661071 | 0.93 | DDB1 (0.52) | DDB1CRBNALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL19208963 | 0.86 | DDB1 (0.53) | DDB1CRBNALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL8395079 | 0.86 | DDB1 (0.49) | DDB1CRBNALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL22294005 | 0.85 | KMT2A (0.52) | DDB1CRBNALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL17162725 | 0.83 | DDB1 (0.44) | DDB1CRBNALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL8392662 | 0.83 | DDB1 (0.49) | DDB1CRBNALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL18548338 | 0.83 | DDB1 (0.49) | DDB1CRBNALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL1912598 | 0.83 | DDB1 (0.49) | DDB1CRBNALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL18493339 | 0.81 | DDB1 (0.54) | DDB1CRBNALDH1A1MAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617867-B2 | Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2026-05-05 | — | — | US | disclosed |
| CN-115103691-B | Pharmaceutical composition containing antibody drug conjugate and application thereof | 苏州盛迪亚生物医药有限公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-119185572-A | Ligand-drug conjugate of irinotecan analogue, preparation method and application thereof | 江苏恒瑞医药股份有限公司 | 2024-12-27 | — | — | CN | disclosed |
| CN-118903456-A | Ligand-drug conjugate of irinotecan analogue, preparation method and application thereof | 江苏恒瑞医药股份有限公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-118806924-A | Ligand-drug conjugate of irinotecan analogue, preparation method and application thereof | 江苏恒瑞医药股份有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-112512591-B | Ligand-drug conjugate of irinotecan analogue, preparation method and application thereof | 江苏恒瑞医药股份有限公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-114456186-B | Camptothecine derivative and ligand-drug conjugate thereof | 成都百利多特生物药业有限责任公司 | 2023-10-20 | — | — | CN | disclosed |
| EP-4227310-A1 | CAMPTOTHECIN DERIVATIVE AND LIGAND-DRUG CONJUGATE THEREOF | Sichuan Baili Pharmaceutical Co. Ltd. (CN) | 2023-08-16 | — | — | EP | disclosed |
| US-20230241242-A1 | PREPARATION METHOD FOR ANTIBODY MEDICAMENT CONJUGATE | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230241242-A1 | PREPARATION METHOD FOR ANTIBODY MEDICAMENT CONJUGATE | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2023-08-03 | — | — | US | disclosed |
| EP-4129345-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY DRUG CONJUGATE AND USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2023-02-08 | — | — | EP | disclosed |
| EP-4129345-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY DRUG CONJUGATE AND USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2023-02-08 | — | — | EP | disclosed |
| EP-4130045-A1 | PREPARATION METHOD FOR ANTIBODY MEDICAMENT CONJUGATE | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2023-02-08 | — | — | EP | disclosed |
| EP-4130045-A1 | PREPARATION METHOD FOR ANTIBODY MEDICAMENT CONJUGATE | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2023-02-08 | — | — | EP | disclosed |
| CN-115103691-A | Pharmaceutical composition containing antibody drug conjugate and application thereof | 江苏恒瑞医药股份有限公司 | 2022-09-23 | — | — | CN | disclosed |
| CN-115103858-A | Preparation method of antibody drug conjugate | 江苏恒瑞医药股份有限公司 | 2022-09-23 | — | — | CN | disclosed |
| CN-114456186-A | Camptothecin derivative and ligand-drug conjugate thereof | 四川百利药业有限责任公司 | 2022-05-10 | — | — | CN | disclosed |
| US-20210353764-A1 | LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2021-11-18 | — | — | US | disclosed |
| EP-3858386-A1 | LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2021-08-04 | — | — | EP | disclosed |
| WO-2020063676-A1 | LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 江苏恒瑞医药股份有限公司 | 2020-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12617867-B2 | Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof | EGFR, CCKAR, MET | DDB1 3361/4885CRBN 618/4885ALDH1A1 2533/4885 |
| US-20210353764-A1 | LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | GLP1R, ADGRF1, CCKAR | DDB1 4499/4885CRBN 2087/4885ALDH1A1 1945/4885 |
| US-20230241242-A1 | PREPARATION METHOD FOR ANTIBODY MEDICAMENT CONJUGATE | FCGR1A, FCGR3B, FCGR2A | DDB1 2399/4885CRBN 276/4885ALDH1A1 1347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.